НОВЫЕ НАПРАВЛЕНИЯ В ТЕРАПИИ ОСТЕОПОРОЗА - ПРИМЕНЕНИЕ МОНОКЛОНАЛЬНЫХ ЧЕЛОВЕЧЕСКИХ АНТИТЕЛ К RANKL (ДЕНОСУМАБ)

Обзор литературы посвящён патогенетической обоснованности, эффективности и безопасности применения деносумаба в терапии постменопаузального остеопороза. Обсуждается механизм действия препарата, сходства и отличия по отношению к другим препаратам для лечения остеопороза. Подробно представлены результаты II и III фаз клинических исследований деносумаба, в том числе в сравнении с алендроновой кислотой и возможности назначения деносумаба после лечения бисфосфонатами. Отдельное внимание уделяется безопасности и практическим аспектам терапии деносумабом

1. Beck T.J., Lewiecki E.M., Miller P.D., Felsenberg D., Liu Y., Ding B., Libanati C.: Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. // J. Clin Densitom, 2008, Vol. 11, pp. 351-359

2. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., Holmes G.B., Dunstan C.R., DePaoli A.M.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. // J. Bone Miner Res, 2004, Vol. 19, pp. 1059-1066

3. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., Holmes G.B., Dunstan C.R., DePaoli A.M. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. // J. Bone Miner Res. 2004, Vol. 19, pp. 1059-1066

4. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Wang H., Liu Y., San Martin J.: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. // J. Clin Endocrinol Metab, 2008, Vol. 93, pp. 2149-2157

5. Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., de Gregorio L.H., Hadji P., Hofbauer L.C., Alvaro-Gracia J.M., Wang H., Austin M., Newmark R., Libanati C., San Martin J., Bone H.G.: Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized blinded, phase 3 trial. // J. Bone Miner Res, 2009, Vol. 24, pp. 153-161

6. Cummings S.R., Martin J.S., McClung M.R., Siris E.S., Eastell R., Reid I.R., Delmas P., Zoog H.B., MattAustin M.S., Wang A., Kutilek S., Adami S., Zanchetta J., Libanati C., Siddhanti S., Christiansen C., for the Freedom trial.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. // NEJM., 2009, Vol. 361, pp. 756-765

7. Eastell R., Christiansen C., Grauer A., Kutilek S., Libanati C., McClung M.R., Reid I.R., Resch H., Siris E., Uebelhart D., Wang A., weryha G., Cummings S.R.: Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. // J. Bone Mineral Research, 2011, Vol. 26, pp. 530-537

8. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L.: Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin Invest, 2003, Vol. 111, pp. 1221-1230

9. Genant H.K., Engelke K., Hanley D.A., Brown J.P., Omizo M., Bone H.G., Kivitz A.J., Fuerst T., Wang H., Austin M., Libanati C.: Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone density. // J. Bone, 2010, Vol. 47, pp. 131-139

10. Kendler D.L., Bessette L., Hill C.D., Gold D.T., Horne R., Varon S.F., Borenstein J., Wang H., Man H.S., Wagman R.B., Siddhanti S., Macarios D., Bone H.G.: Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. // J. Osteoporosis International, 2010, Vol. 21, pp. 837-846

11. Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., Man H., Martin J.S., Bone H.G.: Effects of Denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alensronate therapy. JBMR, 2010, Vol. 25, pp. 72-81

12. Lewiecki E.M., Miller P.D., McClung M.R., Cohen S.B., Bolognese M.A., Liu Y., Wang A., Siddhanti S., Fitzpatrick L.A., AMG Bone Loss Syudy Group.: Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. // J. Bone Miner Res, 2007, Vol. 22, pp. 1832-1841

13. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., Peacock M., Miller P.D., Lederman S.N., Chesnut C.H., Lain D., Kivitz A.J., Holloway D.L., Zhang C., Peterson M.C., Bekker P.J., AMG 162 Bone Loss study group.: Denosumab in postmenopausal women with low bone mineral density // N. Engl J. Med, 2006, Vol. 354, pp. 821-831

14. McClung M.R.: Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. // Curr Osteoporos Rep. 2006, Vol. 4, pp.28-33

15. Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., Liu Y., San Martin J., Amg Bone Loss Study Group.: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. // J. Bone, Vol. 43, pp. 222-229

16. Miller P.D., Wagman R.B., Peacock M., Lewiecki E.M., Bolognese M.A., Weinstein R.L., Ding B., San Martin J., McClung M.R.: Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. // J. Clin Endocrinol and Metabolism, 2011, Vol. 96, pp. 394-402

17. Racher T.D., Khosla S., Hofbauer L.C.: Osteoporosis: now and the future. // New Horizons, 2011, Vol. 377, pp. 1-11 published online

18. Raisz L.G.: Pathogenesis of osteoporosis: concepts, conflicts, and prospects. // J. Clinical Investigation, 2005, Vol. 115, pp. 3318-3325

19. Reid I.R., Miller P.D., Brown J.P., Kendler D.L., Fahrleitner-Pammer A., Valter I., Maasalu K., Bolognese M.A., Woodson G., Bone H., Ding B., Wagman R.B., San Martin J., Ominsky M.S., Dempsyer D.W., Denosumab phase 3 histology study group // J. Bone Mineral Res, 2010, Vol. 25, pp. 2256-2265

20. Seeman E., Delmas P.D., Hanley D.A., Sellmayer D., Cheung A.M., Shane E., Kearns A., Thomas T., Boyd S.K., Bountroy S., Bogado C., Majumdar S., Fan M., Libanati C., Zanchetta J.: Microarchitectural deteriorayion of cortical and trabecular bone: differing effects of denosumab and alendrinate. // J. Bone Miner Res, 2010, Vol. 25, pp. 1886-1894

21. Simonet W.C., Lacey D.L., Dunstan C.R., et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. // J. Cell, 1997, Vol. 89, pp. 309-319

22. Smith M.R., Saad F., Egerdie B., Szwedowski M., Tammela T.L., Ke C., Leder B.Z., Goessl C.: Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. // J. Urol, 2009, Vol. 182, pp. 2670-2675

23. Watts N.B., Bilezikian J.P., Camacho P.M., Greenspan S.L., Harris S.T., Hodgson S.F., Kleerekoper M., Luckey M.M., McClung M.R., Pollack R.P., Petak S.M.: American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. // Endocrine Practice, 2010, Vol. 16, suppl 3, pp. 1-37.